Company: CDT
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001641172-25-024140
Chunk: 128

Company: CDT Equity Inc.
Filing Date: 2025-08-14
Form: 10-Q
Item: Part I, Item 8
Chunk 128
---
 against a database of over 800 disease signatures. Sarborg’s insights have directly informed two new combination
patent filings, strengthening our intellectual property portfolio. In addition, Equity has initiated pre-clinical in-vitro models to
explore new indications, guided by AI-insights without human intervention. We will seek an exit through third-party license deals following
successful in vitro and in vivo pre-clinical trials, entering into agreements with third-parties to pursue further development, FDA approval,
commercialization and marketing of our assets . We continue to evaluate novel artificial intelligence and cybernetics approaches to drug
re-purposing, intellectual property and asset selection to give CDT a competitive advantage.

31

The Sarborg
Agreement, entered into between the Company and Sarborg on December 12, 2024 is designed to address longstanding challenges in the pharmaceutical
sector, in particular by reducing human error in critical decision-making processes in both clinical development and asset identification.
By integrating Sarborg’s algorithmic AI/cybernetics technology, CDT aims to enhance efficiency, lower costs, and accelerate timelines
by minimizing human intervention, ultimately optimizing the drug development cycle and giving CDT a competitive advantage in the sector.

Through
this relationship, CDT will gain access to cutting-edge predictive models and dashboards, enabling the Company to evaluate drug candidates,
streamline clinical trials, and optimize asset management with real-time data. These tools will drive faster, more accurate decisions,
improving efficiency and reducing costs. By leveraging these insights, CDT can differentiate itself in a competitive sector and gain unique
data-driven insights that position the Company for success across both its current and future asset portfolio.

A further
partnership with Manoira enables CDT Equity to expand the scope of its drug portfolio into the animal health market in a cost-efficient
manner. This collaboration allows us to accelerate the understanding of the mechanism of action, safety, and potential efficacy of its
portfolio across multiple species, while retaining 100% ownership of all data and intellectual property generated relating for human applications.
This is expected to enhance the core human therapeutic pipeline but also opens potential new revenue streams in the high-growth veterinary
market.

Repositioning
CDT Equity enables the company to explore multiple opportunities in the healthcare, biotech and broader technology innovation. The Board
continue to evaluate a cryptocurrency treasury reserve strategy, working with consultants to best advise a novel market which has seen
significant recent activity and success for respective stakeholders. Long-term exposure to